Sumary of Convalescent plasma does not reduce risk of intubation or death for COVID-19 hospitalized patients:
- However, the study also revealed that the antibody profile in the blood of people who have had the virus is extremely variable and this may modify the response to the treatment.
- The Canadian-led international research team also found that patients receiving convalescent plasma experienced significantly more serious adverse events than those receiving standard care.
- The clinical trial, called CONCOR-1, stopped enrolment early in January 2021 after its independent data safety monitoring committee recommended the study was unlikely to demonstrate a benefit of convalescent plasma even if more patients were enrolled.
- A secondary discovery was that convalescent plasma had highly variable donor antibody content due to the highly variable immunological response to the virus.
- Different antibody profiles in the convalescent plasma were observed to significantly impact whether or not patients experienced intubation or death.
- Unfavourable antibody profiles, meaning low antibody titres, non-functional antibodies or both, was associated with a higher risk of intubation or death.